Description
Subscribe for FREE HERE.FDA turmoil impacts key drug decisions, Compass’s phase 3 psilocybin data spooks investors, and Exelixis soars on cancer results (June 20–26, 2025).
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster